Ocular manifestations of Cancer drugs

Antibody drug conjugates (ADCs) are innovative cancer therapies that combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic drugs, targeting cancer cells more precisely. However, the use of ADCs may be associated with ocular side effects, ranging from mild symptoms such as blurred vision to more severe complications like retinal toxicity, highlighting the need for careful monitoring and management in clinical practice.

Read more!